AERIAL®: Changes in health and functional status in patients with COPD during therapy with Spiolto® Respimat®

Study identification

• EU PAS number:
  EUPAS18745
• Study ID:
  34041
• Official title and acronym:
  AERIAL®: Changes in health and functional status in patients with COPD during therapy with Spiolto® Respimat®
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® after approximately 6 weeks in routine clinical practice.
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Multiple centres: 144 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:18/10/2016

Actual:18/10/2016

Study start date

Planned:30/04/2017

Actual:26/05/2017

Data analysis start date

Planned:31/08/2018

Actual:24/05/2019

Date of final study report

Planned:31/12/2018

Actual:18/12/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Pharma GmbH&Co.KG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable